AB Science S.A. (ABSCF)

Market Cap	105.77M
Revenue (ttm)	1.16M
Net Income (ttm)	-6.47M
Shares Out	n/a
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	8,458
Open	1.570
Previous Close	0.900
Day's Range	1.570 - 1.570
52-Week Range	0.800 - 2.700
Beta	1.69
RSI	31.33
Earnings Date	Apr 30, 2025

About AB Science

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 57
• Stock Exchange: OTCMKTS
• Ticker Symbol: ABSCF

Financial Performance

In 2023, AB Science's revenue was 970,000, an increase of 1.25% compared to the previous year's 958,000. Losses were -11.99 million, -11.97% less than in 2022.

Financial numbers in EUR